• Offers targeted immunomodulation to treat depigmentation (vitiligo) and inflammatory skin conditions by inhibiting JAK1/JAK2 pathways.
• Enables localized topical therapy, which may reduce systemic side-effects compared to oral JAK inhibitors.
• In clinical cases, supports repigmentation of vitiligo patches and remission of inflammatory symptoms in atopic dermatitis.
• 5 g format allows precise application on affected areas (e.g., face, hands, limbs) under specialist oversight.
• Great option when conventional therapies (topical steroids, calcineurin inhibitors) are insufficient or not suitable

1. Cleanse the affected skin area and pat dry.
2. Apply a thin layer of Ruxotib Cream to the affected area twice daily (morning and evening) or as directed by your dermatologist.
3. Wash your hands after application unless the hands are the treatment area. Avoid covering with occlusive dressings unless advised by your doctor.
4. Continue treatment consistently—visible improvement may take weeks to months. Follow-up with your healthcare provider to assess progress.
5. If no improvement after 8-12 weeks (or per physician review), re-evaluate therapy. Discontinue if serious adverse reactions occur.

1. What conditions does Ruxotib Cream treat?
It is indicated for non-segmental vitiligo and mild to moderate atopic dermatitis (in adults and adolescents ≥12 years) when standard topical therapies are not sufficient.

2. How quickly will I see results?
Response may take several weeks; repigmentation in vitiligo can be gradual and dependent on consistent use and adjunct therapies (e.g., phototherapy).

3. Can I apply it all over the body?
Use is typically limited to affected area(s); applying to large surface areas without medical supervision may increase systemic exposure—limit according to your doctor’s advice.

4. Are there side-effects?
Possible effects include local irritation, redness, or infection. Because this is an immune-modulating agent, patients must be monitored for infections, malignancy risk or blood disorders.

5. What happens if I stop using it early?
If treatment is discontinued before full effect, disease may relapse or pigmentation may fade again—continued medical supervision is recommended.

• For topical use only on intact skin. Avoid applying to broken skin, open wounds or mucous membranes (eyes, mouth, genital area).
• Use under strict medical supervision, especially in patients with immune compromise, infections, or those on systemic immunosuppressants—do not use concomitantly with other JAK inhibitors or potent immunosuppressives.
• Not recommended for children under 12 years of age as safety and efficacy have not been established.
• Pregnant or breastfeeding individuals should consult a physician before use. Monitor for adverse effects including signs of infection, skin thinning, or systemic absorption.
• Store the tube in a cool, dry place (≈ 20-25 °C) away from direct sunlight and out of reach of children.